Opto-Microfluidics: A Rapid and Sensitive Platform for Biological Diagnostics

在澳大利亚，25岁以上的人中每四人中就有一人患有糖尿病相关疾病，相关的经济成本每年超过30亿美元。一种用于持续血糖监测的微型设备将帮助患者管理疾病，带来巨大的个人、临床和社会利益。预期寿命将随着生活质量的提高而增加。将这种微型设备与胰岛素输送相结合，将实现“人工胰腺”，彻底改变这种疾病的管理和治疗。该技术还将为其他医疗点医疗诊断设备提供平台，使其能够及早参与这一新兴市场，并巩固澳大利亚在生物纳米技术方面的地位。

One in four people above 25 years suffer from diabetes-related diseases in Australia, with an associated economic cost exceeding $3 billion a year. A microdevice for continuous glucose monitoring would help patients to manage the disease, leading to huge individual, clinical and societal benefits. Life expectancy is expected to increase along with quality of life. Integration of the microdevice with insulin delivery would realise an 'artificial pancreas', revolutionising the management and treatment of the disease. The technology will also provide a platform for other point-of-care medical diagnostic devices, which will allow early participation in this emerging market and cement Australia's position in bionanotechnology.